key: cord-0713401-drpb8069
authors: Patchsung, M.; Homchan, A.; Aphicho, K.; Suraritdechachai, S.; Wanitchanon, T.; Pattama, A.; Sappakhaw, K.; Meesawat, P.; Wongsatit, T.; Athipanyasilp, A.; Jantarug, K.; Athipanyasilp, N.; Buahom, J.; Visanpattanasin, S.; Niljianskul, N.; Chaiyen, P.; Tinikul, R.; Wichukchinda, N.; Mahasirimongkol, S.; Sirijatuphat, R.; Angkasekwinai, N.; Crone, M. A.; Freemont, P. S.; Joung, J.; Ladha, A.; Abudayyeh, O.; Gootenberg, J.; Zhang, F.; Chewapreecha, C.; Chanarat, S.; Horthongkham, N.; Pakotiprapha, D.; Uttamapinant, C.
title: A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance
date: 2022-03-18
journal: nan
DOI: 10.1101/2022.03.17.22272589
sha: a1119b941c137ed866fbe26606faf4674be425d6
doc_id: 713401
cord_uid: drpb8069

Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection, such as multiplexed detection for viral variant surveillance, may limit their widespread adoption. Herein, we developed a robust multiplexed CRISPR-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose SARS-CoV-2 infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)-including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)-all while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool, CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance which can be locally manufactured, may enable sustainable use of CRISPR diagnostics technologies for COVID-19 and other diseases in POC settings.

With emerging VOCs, we re-designed our multiplexed detection platform-with minimal 151 adjustments to our FDA-approved protocol beyond new primers and crRNAs-to concurrently 152 diagnose SARS-CoV-2 infection-via pan-variant detection of the n gene-and discriminate 153 the highly transmissible Delta (B.1.617.2) and Omicron (B.1.1.529) via variant-specific 154 detection of the s gene ( Figure 1B , bottom). Our best design for multiplexed Delta variant 155 detection showed excellent sensitivity (LoD at Ct ~37) and specificity, with no cross-reactivity 156 toward wild-type, Alpha (B.1.1.7), and Omicron SARS-CoV-2. Our Omicron variant 157 detection-which detected the HV69-70 deletion also found in the now extinct Alpha strain-158 was slightly less sensitive (LoD at Ct ~34) and exhibited minimal cross-reactivity with wild-159 type and Delta SARS-CoV-2. 160 161

To sustain SARS-CoV-2 detection and variant surveillance capability in LMICs, we also report 162

here an RT-RPA reaction in which all protein components of RPA were locally produced in 163

Thailand, and demonstrated similar amplification efficiency, including for multiplexed 164 detection, of the locally produced RPA to commercial RPA. Our overall setup ( Figure 1C )-165 an equipment-light, field-deployable, and easy-to-use multiplexed CRISPR-based assay 166

capable of simultaneous detection of SARS-CoV-2 and VOC identification, while maintaining 167 high specificity and sensitivity-can now be prepared with locally manufactured components, 168

providing affordable access of critical reagents for diagnostic and variant surveillance assays 169

to the most vulnerable populations. 170 171

Results 172

Developing multiplexed reverse-transcription RPA for SARS-CoV-2 RNA detection 173

Standard SARS-CoV-2 laboratory diagnostics include the detection of at least two loci, often 174

in a multiplexed manner, as a precaution against escape mutations (Tang et al., 2020) ; we 175

wished to first confer this multiplexed detection capability to our platform. We focused our 176 optimization of multiplexed isothermal amplification on the RPA technique, as we and others 177

(Bao et al., 2020) found another popular isothermal amplification technique, LAMP, to be 178 highly susceptible to carryover contamination, likely due to its generation of large concatemer 179 amplicons that are highly amplificative and resistant to degradation. RPA can also be 180 performed at lower, near ambient temperature, making it more easily deployed for point-of-181 care or field applications. Our previous work identified four sets of RPA primer pairs which 182 enable amplification of the spike (s), nucleocapsid (n), and two regions within the replicase 183 polyprotein 1ab (orf1ab) genes of SARS-CoV-2 (Patchsung et al., 2020) (Figure 1- figure  184 supplement 1A). Their amplification rates were variable, with the primer pair detecting the s 185 gene being the most sensitive (Patchsung et al., 2020) . We found that simply combining two 186 of these primer pairs did not result in amplification of both targets, as the fast-amplifying 187 product of one gene would dominate the reaction ( RNA as a template allowed us to detect both n and s amplicons with similar efficiency ( Figure  198 1-figure supplement 1D). Beyond primer design, we optimized the primer concentration and 199 fine-tuned the n:s primer pair ratio by increasing the n primer pair amount 1.25-1.5-fold, and 200 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint found the n gene detection at these slightly skewed primer pair ratios to improve and match 201 that of the s gene at all RNA concentrations tested (Figure 1-figure supplement 2) . 202 203 Consistent with previous reports (Patchsung et al., 2020; Qian et al., 2020) , we found that 204

RNase H improves RT-RPA efficiency, but reducing RNase H amount in RT-RPA 4-8 fold 205 compared to what we initially reported (Patchsung et al., 2020) further enhanced the reaction 206

( Figure 1-figure supplement 2C ). We reasoned that while RNase H can remove RNA from the 207 RNA:DNA duplex product of RT and accelerate subsequent RPA, excess RNase H may 208 degrade the SARS-CoV-2 RNA template in the starting RNA:primer complex and dampen the 209 enzyme's beneficial effect. 210 211

Optimizing multiplexed CRISPR-based detection for SARS-CoV-2 RNA 212 We established a readout platform for multiplexed RNA amplification, via a multiplexed 213 CRISPR-Cas reaction. Cas13 enzymes with orthogonal collateral cleavage preferences are well 214 characterized; among the variants, Cas13a from Leptotrichia wadei (LwaCas13a) and Cas13b 215

from Prevotella sp. MA2016 (PsmCas13b) have already been demonstrated to work well in 216 tandem, and have been used in combination with multiplexed RPA to detect two synthetic 217 DNA targets (Gootenberg et al., 2018) . We previously set up LwaCas13a-based detection of 218 SARS-CoV-2 RNA, primarily for the s gene, utilizing a FAM-labeled polyU reporter 219 (Patchsung et al., 2020) . To extend the detection to two genes, we expressed and purified 220

PsmCas13b (Figure 1-figure supplement 3) , designed its CRISPR RNA (crRNA) to target the 221 n gene of SARS-CoV-2, and prepared a Cy5-labeled polyA reporter to match with adenine 222 cleavage preference of PsmCas13b. 223 224 We confirmed that PsmCas13b exhibits collateral cleavage of the polyA reporter, thereby 225 eliciting Cy5 fluorescence when its n gene target is present. We empirically optimized the 226 enzyme:crRNA amount used in the detection reaction, as well as the polyA reporter 227 concentration ( Figure 1-figure supplement 4) . Generally, more enzyme, crRNA, and the 228 reporter are needed for the PsmCas13b-based detection compared to conditions used for 229

LwaCas13a, reflecting poorer collateral cleavage kinetics of PsmCas13b, which was 230 previously documented (Gootenberg et al., 2018) and which we also confirmed by performing 231 side-by-side detection reactions with PsmCas13b vs LwaCas13a on the same RPA product 232

( We also explored Cas13d from Ruminococcus flavefaciens (RfxCas13d), which is the most 237 catalytically active of Cas13 orthologs in mammalian applications (Konermann et al., 2018) , 238 as well as its engineered variant, RfxCas13d-RBD, which has an RNA binding domain (RBD) 239 from human protein kinase R fused to RfxCas13d to improve RNA binding (Yin et al., 2020) . 240 However, both RfxCas13d variants exhibited the polyU cleavage efficiency that was lower 241 than that of LwaCas13a (Figure 1-figure supplement 6) . Therefore, we decided to proceed with 242 the current best enzyme pair, LwaCas13a and PsmCas13b, and determine the system's clinical 243 performance in the multiplexed gene detection of SARS-CoV-2 (Figure 1-figure supplement 244 6). 245 246 We screened solubility/stability-enhancing additives in the reactions to improve the efficiency 247 of the multiplexed RT-RPA and CRISPR reaction. Triglycine boosted the multiplexed RPA 248 reaction the most, consistently increasing the positive rates ( be combined with that of triglycine in the multiplexed RPA step, and we obtained the best 253 signal-to-noise upon multiplexed detection when both additives were used in their respective 254 reactions. (Figure 1-figure supplement 7C ). Empirical adjustments to the Cas:crRNA ratio and 255 total amount, and reaction buffers further improved the multiplexed Cas reactions (Figure 1-256 figure supplement 9). 257 258

Lyophilized RPA and CRISPR-Cas reaction pellets for portable SARS-CoV-2 RNA 259 detection 260 We simplified liquid handling steps involved in the amplification and detection reactions and 261

increased the shelf-lives of protein/RNA components of the reactions by storing them in 262 lyophilized forms. All components required for either multiplexed RT-RPA or the CRISPR-263

LwaCas13a-based detection, aside fr6om potassium acetate and magnesium acetate for RPA, and magnesium chloride for CRISPR-Cas reaction, can be lyophilized together in the 265 presence of cryoprotective trehalose with minimal loss of activity upon reconstitution ( Figure  266 1 Analysis of clinical specificity, analytical sensitivity (the limit of detection) and clinical 281 sensitivity of the multiplexed detection of SARS-CoV-2 RNA 282 We performed clinical validation with a lyophilized premixed RT-2xRPA formulation, as it 283 had the highest detection sensitivity and suitable features for POC use. We found that the 284 multiplexed RPA and Cas13a/b-based detection are specific for the s and n genes of SARS-285

CoV-2, and exhibited no cross-reactivity upon using RNA input from other common human 286 coronaviruses, including human coronavirus OC43 (hCoV-OC43), hCoV-NL63, and hCoV-287 229E (Figure 2A ). Using serially diluted RNA extracts from cultured SARS-CoV-2 in Vero 288 cells (clinical isolate hCoV-19/Thailand/Siriraj_5/2020; GISAID accession ID: 289 EPI_ISL_447908), we determined the limit of detection (LoD) of the optimized multiplexed 290 detection of the SARS-CoV-2 s and n genes to be at Ct ~37 ( Figure 2B ). 291 292

The clinical performance of the multiplexed detection platform on RNA extracts from 136 293 nasopharyngeal and throat swab clinical samples, 91 of which are SARS-CoV-2 positive by 294

RT-qPCR (Ct of the n gene ranging from ~13-39), matched well with the characterized 295 specificity and LoD ( Figure 2C -G). We were able to identify all 45 SARS-CoV-2-negative 296 samples (100% specificity, Figure 2C ). Among 91 RT-qPCR-positive samples, we were able 297 to detect both s and n genes in 85 samples and at least either the s or the n gene in three other 298 one sample, within 60 min of the multiplexed CRISPR reaction ( Figure 2D , E). We were able 299 to detect both genes in samples with Ct as high as 37.5 ( Figure 2F ). The clinical sensitivity of 300 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint our multiplexed detection within the determined LoD (Ct ~37) is 100% for the detection of 301 either the s or n gene of SARS-CoV-2, and 95% for the detection of both genes ( Figure 2G ). 302

For the full range of Ct's we encountered in clinical samples, the clinical sensitivity is 95-97% 303 for at least one gene detected. Due to extensive optimizations, the limit of detection of our 304 multiplexed detection scheme with lyophilized reagents are even higher than those of freshly 305 prepared singleplex RPA and CRISPR reactions for SARS-CoV-2 s gene we previously 306

reported (Patchsung et al., 2020 ) (LoD Ct ~33.5). 307 308

In addition to performing multiplexed detection with LwaCas13a and PsmCas13b, we explored 309 the use of LwaCas13a and crRNA combinations to detect both s-and n-gene RPA amplicons 310

( Figure 2B -G, LwaCas13a-based dual S/N gene detection is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint sequence context likely plays a key role, short mismatches may still permit non-cognate  351  crRNA: target recognition, and longer mismatches may allow formation of RNA bulges which  352  minimally interfere with crRNA:target base pairing, also resulting in non-cognate target  353  recognition and Cas activation. We thus decided to empirically test three different indel lengths  354  when we selected SARS-CoV-2 variant-specific mutations: a three-nucleotide deletion (S:  355 Y144Δ, specific for Alpha); two six-nucleotide deletions (s:HV69/70Δ, specific for Alpha and 356

Omicron BA.1 and BA.3; and s:EF156/157∆R158G; specific for Delta); and a nine-nucleotide 357 deletion (orf1ab:SGF3675-3677Δ; specific for Alpha) ( Figure 3A and Figure 3 - figure  358 supplement 1). We also tested the detection of one single-nucleotide substitution (S:T22917G, 359 resulting in L452R mutation; specific for Delta) and incorporated a synthetic mismatch in our 360 crRNA design (Figure 3-figure supplement 2 ). 361 362 We designed corresponding RPA primers and LwaCas13a crRNAs for all five mutation-363 specific CRISPR-based detection ( five SARS-CoV-2 variant-specific mutation detection reactions showed SARS-CoV-2 RNA-366 dependent signal but exhibited different levels of selectivity for their target variants. The two 367 six-nucleotide deletion detections performed the best: EF156/157∆R158G was highly specific 368

for Delta, with no cross-reactivity with Wuhan, Alpha, or Omicron strains; HV69/70Δ was also 369 highly specific for Alpha and Omicron as designed, but showed low-level cross-reactivity with 370

Wuhan and Delta. Y144Δ, SGF3675-3677Δ and L425R showed clear detection preference for 371

Alpha, Alpha, and Delta respectively, but background signals from other strains were 372 significant. We thus proceeded with the two best-performing variant-specific detection 373

reactions-EF156/157∆R158G and HV69/70Δ-for subsequent experiments. 374 375 We characterized the limit of detection of the singleplex EF156/157∆R158G-based detection 376 using a dilution series of RNA extracted from cultured SARS-CoV-2 Delta strain, and found 377 the detection to have an excellent LoD, capable of detecting Delta RNA with Ct of up to ~38 378

( Delta-specific detection of the s gene with the PsmCas13b-based pan-SARS-CoV-2-strain 381 detection of the n gene in a multiplexed format ( Figure 1B ). Using the premixed, lyophilized 382 and multiplexed formulation as previously described, we confirmed that the excellent LoD of 383

Delta-specific reaction was maintained in the multiplexed format ( Figure 3C and Figure 3-384 figure supplement 6). Furthermore, the LwaCas13a-based Delta-specific multiplexed detection 385 was able to correctly identify all of twenty Delta patient specimens (Ct 13-27), with no cross-386 reactivity toward ten Alpha clinical specimens (Ct 17-31) ( Figure 3D ). The PsmCas13b-based 387 pan-strain detection was fully functional, detecting the presence of SARS-CoV-2 in this same 388 set of thirty clinical samples. 389 390

With the recent emergence of the Omicron variant, we explored the use of the HV69/70Δ-391 based detection for Omicron identification. We also performed additional cross-reactivity 392 evaluation with higher RNA titer at Ct ~25 since we observed sporadic cross-reactivity in the 393 previous experiment ( Figure 3B and Figure 3 -figure supplement 7). We found that the 394 HV69/70Δ-based detection was able to distinguish Alpha and Omicron variants from other 395 variants even at higher RNA titer. Next, we demonstrated that the singleplex HV69/70Δ-based 396 detection was sensitive to RNA with Ct up to ~34 upon testing with a dilution series of Omicron is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Ct ~34 in a multiplexed format (LwaCas13-based detection of Omicron HV69/70Δ s signature,  401 and PsmCas13b-based pan-strain n gene detection) ( Figure 3E , Figure 3 -figure supplement 6). 402

In addition, we were able to detect the HV69/70Δ s mutation as well as the SARS-CoV-2 n 403 gene in fifteen Omicron clinical specimens (Ct 16-22), using the HV69/70Δ-based multiplexed 404 detection approach ( Figure 3F ). 405 406

Combining multiplexed RPA and Cas13-based detection in a single step 407

To simplify usage and minimize the risk of carryover contamination, we formulated a one-pot 408 protocol which combined components of multiplexed RPA and Cas13-based detection in a 409

single reaction tube. We first tested a previously reported one-pot SHINE protocol (Arizti-Sanz 410 et al., 2020) for the detection of SARS-CoV-2 S gene, but saw that its analytical sensitivity is 411 poorer than our conventional two-step amplification and detection in separate pots by ~10-100-412

fold. Realizing that concentrations of RPA components in SHINE are diluted by 2-fold 413 compared to the two-step variant, potentially hampering performance of RPA in the one-pot 414 reaction, we re-formulated a one-pot recipe in which final concentrations of all components are 415 as close to those in our optimized two-step variant as possible. We also switched the reaction 416 temperature to be 39 °C, found to be optimal for combined RPA and Cas13-based detection 417

( Figure 4 -figure supplement 1). We tested the optimized one-pot multiplexed RPA 418 amplification of the s and n genes and concurrent detection by LwaCas13a programmed with 419 s-and n-targeted crRNAs, and found its analytical sensitivity to be on par with the two-step 420 protocol ( Figure 4A ). 421 422

Direct visualization of multiplexed Cas13-based detection 423

To facilitate the use of a multiplexed CRISPR reaction in point-of-care settings, we switched 424 the fluorophore labels of the PsmCas13b-polyA reporter, from Cy5 to rhodamine X (ROX). 425

The ROX-based polyA reporter generates slightly higher levels of signal-to-noise upon 426

PsmCas13b-mediated cleavage compared to the Cy5-based reporter ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint from either DNA or RNA samples for subsequent CRISPR-Cas13a detection ( Figure 4E -4F). 451

The optimized in-house RT-RPA can be used in a multiplexed amplification reaction of the s 452 and n genes, coupled to LwaCas13a-based detection with s-and n-targeted crRNAs (G) and 453

can be lyophilized without loss in detection sensitivity ( Figure 4H is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Expression and purification of protein components of RPA 513

We used near-identical expression and cell lysis protocols for UvsX, UvsY, gp32, and Bsu LF, 514 but the purification step and final storage buffer conditions were different for each enzyme, as 515

given below. 516 517

An expression plasmid for UvsX, UvsY, gp32, or Bsu LF was transformed into E. coli 518 BL21(DE3) cells. The cells were grown in LB medium at 37°C until OD600 reached 0.7-0.8. 519

Protein expression was induced using the following concentrations of isopropyl-β-D-520 thiogalactopyranoside (IPTG): 1 mM for UvsX and UvsY; 0.2 mM for gp32; and 0.5 mM for 521

Bsu LF. The cells were grown for additional 16 hours at 16°C and harvested by centrifugation. 522

The cell pellet was resuspended in lysis buffer (50 mM sodium phosphate pH 8.0, 500 mM 523 sodium chloride, 10 mM imidazole). Phenylmethylsulfonyl fluoride (PMSF) was added into 524 resuspended solution at 1 mM final concentration followed by sonication for a total burst time 525 of 3 minutes (3 sec on for short burst and 9 sec off for cooling). The cell lysate was clarified 526 by centrifugation at 27,000×g for 30 minutes at 4 °C. Nickel-nitrilotriacetic acid (Ni-NTA) 527 agarose beads (Qiagen) was washed with two column volumes of water and equilibrated with 528 lysis buffer. The clarified cell lysate was incubated with the Ni-NTA agarose beads (Qiagen) 529 at 4 °C for 40 minutes. The column was washed with ten column volumes (CVs) of washing 530 buffer (50 mM sodium phosphate pH 8.0, 500 mM sodium chloride, and 20 mM imidazole), 531 and the bound proteins were eluted with elution buffer (50 mM sodium phosphate pH 8.0, 500 532 mM sodium chloride, 250 mM imidazole). 533 534

For UvsX, the protein was further purified by Heparin Sepharose Fast Flow (GE Healthcare 535

Life Sciences) with a linear gradient of 0.1-1 M NaCl in Buffer A (20 mM Tris-HCl pH 8, 5 536 mM β-mercaptoethanol (βME)). Proteins were concentrated and stored in 20 mM Tris-HCl pH 537 8.0, 500 mM NaCl, and 40% (v/v) glycerol at −20 °C. 538 539

For UvsY, the protein was further purified by Heparin Sepharose Fast Flow (GE Healthcare 540

Life Sciences) with a linear gradient of 0.1-1 M NaCl in Buffer A (20 mM Tris-HCl pH 8, 5 541 mM βME). Afterward, proteins were dialyzed against 20 mM Tris-HCl pH 7.5, 400 mM NaCl, 542 20% (v/v) glycerol and 5 mM βME, and the glycerol concentration adjusted to be 50% (v/v) 543

with the addition of UvsY freezing buffer (20 mM Tris-HCl pH 7.5, 400 mM NaCl, and 80% 544

(v/v) glycerol). Protein aliquots were stored in 20 mM Tris-HCl pH 7.5, 400 mM NaCl, and 545 50% (v/v) glycerol at −20 °C. 546 547

For gp32, eluted protein fractions were dialyzed against 20 mM Tris-HCl pH 7.5, 400 mM 548

NaCl, and 5 mM βME, and the glycerol concentration adjusted to be 50% (v/v). Protein aliquots 549

were stored in 10 mM Tris-HCl pH 7.5, 200 mM NaCl, and 50% (v/v) glycerol at −20 °C. 550 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Expression and purification of Cas enzymes 559

LwaCas13a expression and purification 560

LwaCas13a was expressed from pC013-His6-Twinstrep-SUMO-LwaCas13a (Addgene: 561 #90097) and purified as previously described (Patchsung et al., 2020) . 562 563

PsmCas13b expression and purification 564

Escherichia coli BL21 (DE3) transformed with pC0061-His6-Twinstrep-SUMO-PsmCas13b 565 (Addgene: #115211) were grown in LB media containing 25 µg/mL ampicillin, and the protein 566 expression induced by the addition of 500 µM IPTG at 16 °C for overnight. Cells were 567

collected by centrifugation at 8,000 rpm for 20 min at 4 °C and the supernatant was discarded. 568

The cell pellet was resuspended in extraction buffer (50 mM Tris-HCl, 500 mM NaCl, 1 mM 569 DTT, 1x protease inhibitor cocktail, 0.25 mg/mL lysozyme, 5 mM imidazole, pH 7.5) then 570 lysed by sonication (Sonics Vibracell VCX750) using 40-60% pulse amplitude (on 10 s and 571

off 20 s until completely lysed). The lysate was centrifuged at 15,000 rpm for 45 min at 4 °C, 572 and the soluble fraction filtered through a 0.45 µm polyethersulfone membrane and loaded into 573

Chelating Sepharose TM Fast Flow column which was pre-loaded with 0.2 M NiSO4 and pre-574 equilibrated with binding buffer (50 Tris-HCl, 500 mM NaCl, 5 mM imidazole pH 7.5). The 575 column was washed with 5 column volumes of binding buffer, 6 column volumes of washing 576 buffer (50 Tris-HCl, 500 mM NaCl, 50 mM imidazole pH 7.5) and eluted with 6 column 577 volumes of elution buffer (50 Tris-HCl, 500 mM NaCl, 500 mM imidazole pH 7.5). The 578

fractions containing His-Twinstrep-SUMO-PsmCas13b were pooled and exchanged with 579 SUMO cleavage buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0) at 4 °C overnight. 580 581

The SUMO tag was cleaved with Ulp1 SUMO protease (Addgene #64697) using 10:1 of 582 SUMO substrate by incubation at room temperature for 5 h. The reaction was adjusted to pH 583 6.0 and filtered with 0.45 µm polyethersulfone membrane before loading into HiTrap SP HP 584 column which was equilibrated with binding buffer (50 mM phosphate pH 6.0, 200 mM NaCl). 585

The protein was washed and eluted with 50 mM phosphate, 200 mM NaCl with pH ranging 586 from 6.0, 6.5, 7.0, 7.5, and 8.0, followed by 50 mM Tris pH 8.0, 1 M NaCl. The PsmCas13b 587 fractions were pooled, concentrated, exchanged buffer using centricon 30k, diluted to a 588 concentration of 1.2 mg/mL, and stored at -80 °C in storage buffer (50 mM Tris-HCl, 600 mM 589 NaCl, 5 % glycerol, 2 mM DTT). 590 591

RfxCas13d and RfxCas13d-RBD expression and purification 592 E. coli BL21 (DE3) cells transformed with CMS1371 (for His6-MBP-RfxCas13d expression) 593 or CMS1372 (for His6-MBP-RfxCas13d-dsRBD) plasmid were grown in LB media containing 594 100 µg/mL ampicillin, and the recombinant gene expression induced by the addition of 500 595 µM IPTG at 16 ºC for overnight. Cells were collected and lysed as for PsmCas13b. Following 596 lysate clarification, the soluble fraction was filtered through 0.2 µm polyethersulfone 597 membrane and purified by HisTrap FF column connected to FPLC system. The column was 598 pre-equilibrated with binding buffer (50 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole; pH 599 7.5). The soluble fraction was loaded at 2 mL/min, washed with 5 column volumes of binding 600 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint buffer. The recombinant protein was eluted in linear gradient of elution buffer (50 mM Tris-601 HCl, 0.5 M NaCl, and 0.5 M imidazole; pH 7.5). The eluted fractions were pooled and dialyzed 602

with 50 mM Tris-HCl, 0.5 mM EDTA, 1 mM DTT and 200 mM NaCl; pH 7.5 at 4 ºC for 3 603 hours, before proceeding to MBP tag removal. 604 605

The MBP tag was cleaved with ultraTEV protease using 20:1 substrate: protease ratio in 50 606 mM Tris-HCl, 0.5 mM EDTA, 1 mM DTT and 200 mM NaCl; pH 7.5. The reaction mixture 607 was incubated at 4 ºC for overnight with gentle shaking before applied onto HisTrap column, 608

which was pre-equilibrated with (50 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole; pH 7.5). 609

The flow-through and unbound fractions containing RfxCas13d and RfxCas13d-dsRBD 610 protein were then collected while retained MBP and other contaminants were later washed out 611 with high concentration of imidazole. The purified protein was exchanged against 40 mM Tris, 612 400 mM NaCl; pH 7.5 in DEPC-treated water and concentrated using centricon 30k, and 613 diluted to a concentration of 1.22 mg/mL (for RfxCas13d) and 1.89 mg/mL (for RfxCas13d-614 RBD). 615 616 RPA primers, crRNAs, and RNA reporters 617

The oligonucleotides used are listed in Table S2 . were performed at 37 ºC overnight, treated with DNase I, and purified using phenol-chloroform 626 extraction and alcohol precipitation. 15% acrylamide/7.5 M urea PAGE with GelRed ® 627 (Biotium) staining was used to assess the size and purity of the transcribed product. Gels were 628 imaged on ImageQuant™ LAS 4000 (GE Healthcare); quantifications of produced crRNAs 629

were performed by measuring band densitometries using Fiji ImageJ software (Schindelin et  630 al is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint mediocre NextClade overall quality control status were excluded. The analysis was 660 summarized in Figure 3 -figure supplement 8. The associated dataset was available in Figure  661 3-source data 1. The NextStrain Clades or PANGO lineages were designated to each WHO classified variant 678 of concern as described in Table S1  679 Kit (TwistDx) and EpiScript reverse transcriptase (Lucigen). Sequences of RPA primers used 684 were given in Table S2 . LwaCas13a-based detection reactions were also set up exactly as 685 previously described (Patchsung et al., 2020) , then visualized with HybriDetect lateral-flow 686 strips (Milenia Biotec). Sequences of LwaCas13a-crRNAs for each amplicon were given in 687 Table S2 . 688 689

Optimized multiplexed RT-RPA 690

The optimized reaction condition for multiplexed RT-RPA for the amplification of s and n 691 genes of SARS-CoV-2 with TwistAmp Basic RPA is as follows. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Specific RPA and Cas-based detection methods for relevant figures, see Table S3 and Table  736 S4. 737 738

Lyophilized RT-RPA for multiplexed gene detection 739

An RT-RPA reaction buffer A was prepared from 500 μL 50% (w/v) PEG20000, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Optimizing RPA through titration of protein components 793

Concentrations of the main protein components of RPA (UvsX, UvsY, Gp32, and Bsu LF) 794

were varied as indicated in . We also switched to using RPA primers for the n gene 795 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 40 mM triglycine (Sigma), and 700 nM n gene primers. 5.5 µL of serially diluted SARS-CoV-829 2 RNA was used as a template, and the RT-RPA reactions were allowed to proceed at 42°C for 830 60 min. 831 832

The multiplexed RT-RPA to detect the s and n genes of SARS-CoV-2 was set up in a similar 833 condition as the single-plexed amplification, except for the concentration of specific primers, 834 and the amount of RNA template used. Here, we used the n gene and s gene RPA primers at 835 222 nM and 177 nM, respectively, and add 7 µL of serially diluted SARS-CoV-2 RNA as 836

input. RT-RPA reactions were performed at 42 °C for 60 min, and the RPA products monitored 837 through multiplexed Cas13a/b-based detection as described in the optimized multiplexed 838

Cas13-based detection methods section. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Data availability 1179

The main data supporting the results in this study are available within the paper and its 1180 supplementary information. Raw datasets generated and analysed during the study are available 1181 from the corresponding authors upon reasonable request. 1182 1183 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint (B) Top, dual-gene detection via CRISPR-Cas13a/b for COVID-19 diagnosis. Bottom, dualgene detection for simultaneous COVID-19 diagnosis and SARS-CoV-2 variant identification. LwaCas13a is used to detect a universal, pan-strain region (top) or a variantspecific region (bottom) of the SARS-CoV-2 s gene. PsmCas13b is used to detect a panstrain region of the n gene. The amplified regions of the S and N genes are shown in red and green respectively. (C) Developing simple-to-use SARS-CoV-2 variant surveillance tools which can be locally manufactured. Our multiplexed CRISPR-based detection reactions can be premixed and lyophilized for convenient use and storage; multiplexed RPA and Cas13-based reactions can be combined in one tube; result readouts can be directly observed by eye with low-cost light sources; and RPA and Cas13a/b can be locally produced and formulated. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint values were determined using a Luna one-step RT-qPCR assay targeting the n gene of SARS-CoV-2. At least three independent replicates of the amplification/detection reactions were performed for each SARS-CoV-2 RNA dilution. Top: signal-to-noises (S/N) of FAM (from LwaCas13a-mediated s gene detection) and Cy5 (from PsmCas13b-mediated n gene detection) fluorescence intensities are shown. The S/N threshold for a positive result was set at 2. Noise is defined as the fluorescence intensity generated from a negative sample with water as input performed in parallel. Bottom: positive rates of the detection of the s and n genes from multiplexed CRISPR-based detection at different SARS-CoV-2 RNA input concentrations. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint and a smartphone for image capturing is shown. Smartphone-captured images of FAM and ROX signal generated from multiplexed Cas13a/b-based detection of the s and n genes of SARS-CoV-2. (C) SDS-PAGE analysis of locally produced and purified RPA components: UvsX, UvsY, Gp32, and Bsu polymerase large fragment (Bsu LF). (D) Optimizations of protein concentrations in in-house RPA. RPA reactions with varying concentrations of UvsX, UvsY, Gp32, and Bsu LF were performed with pUC57-2019-nCoV-N plasmid as a DNA template (at 10,000 copies/µl). Thereafter, the RPA products were used in a LwaCas13a-based detection. FAM fluorescence generated over 120 min for each RPA condition is shown. (E, F) Optimally formulated in-house RPA in amplification of N gene of SARS-CoV-2 from pUC57-2019-nCoV-N plasmid (E) and serially diluted SARS-CoV-2 RNA (F). LwaCas13a-based detection was then used to detect n-gene amplicons, with FAM fluorescence intensity generated after 90 min at 37°C shown. (G) Optimized in-house RT-RPA for multiplexed detection. Multiplexed RT-RPA to amplify the s and n genes of SARS-CoV-2 was performed using serially diluted SARS-CoV-2 RNA as a template. Detection of s and n amplicons was monitored through FAM fluorescence signal generated by Cas13amediated s and n gene detection. The reaction was measured after 90 min at 37°C. (H) Lyophilized multiplexed in-house RT-RPA has similar sensitivity as freshly prepared reactions. Amplification and detection of the SARS-CoV-2 s and n gene are as in (G). Data are mean ± s.d. from 3 replicates. RNase-free water was used as input of all negative control reactions.

. CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint RT-RPA using each primer pair was performed with SARS-CoV-2 RNA at two different concentrations as a template. Cas13a-based detection with lateralflow readout was then used to assess successful amplification. Experiments with R1 reverse primers (Qian et al.) and R2 reverse primers (bottom) were performed using different SARS-CoV-2 RNA dilutions, but with an identical control primer pair (F1, R1) included in both sets of experiments, allowing us to compare relative performance of all primer pairs. Based on this screening, we selected the (F4, R1) primer pair for subsequent n gene amplifications. D) Multiplexed RPA reactions with pairwise combinations of RPA primers (4 different primer pairs; 6 pairwise combinations). A multiplexed RPA is individually assessed with a LwaCas13a-based detection reaction, each programmed with a specific crRNA for the SARS-CoV-2 gene, and lateral-flow readout. Successful amplification was marked by production of a strong-colored band at a test band (T), which indicates target-activated Cas13a activity and resulting in efficient cleavage of the FAM-biotin reporter. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (A) Optimizing total primer concentrations in multiplexed RPA with 1:1 malar ratio of n to s primer. Multiplexed RPA for the s and n gene of SARS-CoV-2 was performed using indicated primer concentrations and serially diluted SARS-CoV-2 genomic RNA template. In the second step, generated s and n amplicons were detected using a multiplexed CRISPR-Cas reaction containing LwaCas13a and PsmCas13b enzymes. LwaCas13a is programmed with a crRNA targeting the s amplicon and cleaves a FAM/IABkFQ -functionalized polyU reporter once targetactivated (left), while PsmCas13b is programmed with a crRNA targeting the n amplicon and cleaves a Cy5/IABkRQ-functionalized polyA reporter (right). (B) Fine-tuning primer concentrations in the multiplexed RPA reaction. Multiplexed RPA for the s and n gene of SARS-CoV-2 was performed using indicated primer concentrations, with serially diluted SARS-CoV-2 genomic RNA as a template. Amplicons were detected in a multiplexed CRISPR-Cas reaction, via FAM fluorescence generated from s-targeted LwaCas13a (left) and Cy5 fluorescence from N-targeted PsmCas13b is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint n primers (n), or combined s and n primers (s+n). Endpoint fluorescence intensities of the multiplexed detection reactions (90 min) containing all components for LwaCas13-based detection of the s gene and PsmCas13b-based detection of the n gene were shown. Generated FAM (left) and Cy5 (right) fluorescence indicated cleavage of the reporters by the s-targeted LwaCas13a and the n-targeted PsmCas13b, respectively. For C-F, negative controls have no SARS-CoV-2 RNA template input. Data are mean ± s.d. from 3 replicates. (E) Analytical sensitivity of increasing of RPA pellet. Multiplexed RT-RPA for the s and n gene of SARS-CoV-2 was performed using indicated number of RPA pellets, with diluted SARS-CoV-2 genomic RNA at Ct 37 as a template. Subsequently, the amplicons were detected via FAM fluorescence generated from LwaCas13a-based reaction programmed with sand n-targeted crRNAs.

. CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 18, 2022. ; https://doi.org/10.1101/2022.03.17.22272589 doi: medRxiv preprint (A) Screening for additives that enhance multiplexed RT-RPA. Left: nine additives were assessed in a conventional two-step (RPA, then LwaCas13a-based CRISPR-Cas) SHERLOCK detection for the s gene of SARS-CoV-2. Middle: four active additives were evaluated further in triplicates, using less RNA input. Right: two best-performing additives-triglycine and taurine-were finally assessed in a multiplexed RPA reaction for the s and n gene of SARS-CoV-2. Two serial dilutions of SARS-CoV-2 RNA were used as a template; negative control has no SARS-CoV-2 RNA template input. Generated s and n amplicons were detected in separate LwaCas13a-based detection reactions, whose FAM fluorescence signal is shown. (B) Screening for additives that improve the multiplexed CRISPR reaction. Twenty-two additives were assessed in the multiplexed CRISPR-Cas detection, using an RPA product from a multiplexed. Endpoint FAM (Qian et al.) and Cy5 (bottom) fluorescence intensities were normalized against intensities obtained from the no-additive controls. Data are mean ± s.d. from 3 replicates. L-Arginine EE. 2HCl, L-Arginine ethyl ester dihydrochloride. TMAO, trimethylamine N-oxide. (C) Cumulative benefits of triglycine additive in the multiplexed RPA and betaine monohydrate additive in the multiplexed CRISPR-Cas reaction. Multiplexed RPA to amplify the s and n genes of SARS-CoV-2 was performed in the presence or absence of 40 mM triglycine, using serially diluted SARS-CoV-2 RNA as a template, and multiplexed RPA was allowed to proceed for 25 min at 42 ºC. Multiplexed CRISPR-Cas reactions to detect the s and n amplicons were then performed in the presence or absence of 500 mM betaine. FAM and Cy5 fluorescence signal (indicative of Cas13a-mediated s gene and Cas13b-mediated n gene detection respectively) is shown. RNase-free water was used as input of all negative control reactions. Data are mean ± s.d. from 3 replicates. LwaCas13a-based detection reactions were prepared with or without 5% (w/v) PEG20000 and 6% (w/v) trehalose added as a cryoprotectant. MgCl2 was omitted from all reactions and was added at the rehydration step. The detection was performed at 37 °C using n gene RPA product at various dilution levels and monitored under FAM channel using a real-time thermal cycler. The input volume of the RPA dilutions was 2 μL except for the 1:100 dilution sample in which we used either 2-μL or 4-μL input volume. The end-point fluorescence in tubes was visualized using a BluPAD transilluminator. 

Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme. medRxiv

Amplification-free 1008 detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy

Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, 1011 and Csm6

Nucleic acid 1014 detection with CRISPR-Cas13a/C2c2

Programmed DNA destruction 1017 by miniature CRISPR-Cas14 enzymes

Rapid and 1021 accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform

Duplex lateral flow assay for the simultaneous detection of 1026 Yersinia pestis and Francisella tularensis

Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing

MAFFT multiple sequence alignment software version 1033 7: improvements in performance and usability

SHERLOCK: nucleic acid detection with CRISPR nucleases

Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors

CRISPR/Cas9 systems have off-target 1043 activity with insertions or deletions between target DNA and guide RNA sequences

The reproductive number of the Delta variant of SARS-CoV-2 1046 is far higher compared to the ancestral SARS-CoV-2 virus

Detection of severe acute respiratory syndrome coronavirus 2 1051 and influenza viruses based on CRISPR-Cas12a

Field-deployable viral diagnostics using 1057 CRISPR-Cas13

Engineered CRISPR/Cas12a Enables Rapid SARS-CoV-2 Detection. medRxiv

Enhancement of trans-cleavage activity of 1062 Cas12a with engineered crRNA enables amplified nucleic acid detection

Comparative performance of 1066 CRISPR-Cas12a assays for SARS-CoV-2 detection tested with RNA extracted from 1067 clinical specimens

An 1071 engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and 1072 rapid COVID-19 testing

Clinical validation 1078 of a Cas13-based assay for the detection of SARS-CoV-2 RNA

DNA detection using 1081 recombination proteins

Colorimetric-Luminance Readout for 1083 Quantitative Analysis of Fluorescence Signals with a Smartphone CMOS Sensor

A 1086 smartphone-based diagnostic platform for rapid detection of Zika, chikungunya, and 1087 dengue viruses

An enhanced isothermal 1090 amplification assay for viral detection

Circular polymerase extension cloning for high-throughput cloning 1093 of complex and combinatorial DNA libraries

A dynamic nomenclature proposal for SARS-CoV-2 lineages to 1097 assist genomic epidemiology

Machine 1101 Learning-Driven and Smartphone-Based Fluorescence Detection for CRISPR 1102 Diagnostic of SARS-CoV-2

Fiji: an open-source platform for 1106 biological-image analysis

Amplification-free RNA detection with CRISPR-Cas13

The diagnostic accuracy of 1113 isothermal nucleic acid point-of-care tests for human coronaviruses: A systematic 1114 review and meta-analysis

Laboratory Diagnosis of 1117 COVID-19: Current Issues and Challenges

CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and 1121 single-base specificity

Analytical sensitivity and efficiency comparisons of SARS-1127

CoV-2 RT-qPCR primer-probe sets

Jalview 1130 Version 2--a multiple sequence alignment editor and analysis workbench

Multiplexed CRISPR-based microfluidic platform for clinical 1136 testing of respiratory viruses and identification of SARS-CoV-2 variants

Dynamic Aqueous 1139

Multiphase Reaction System for One-Pot CRISPR-Cas12a-Based Ultrasensitive and 1140 Quantitative Molecular Diagnosis

A) LwaCas13a-based detection of a diluted RPA product at different concentration of LwaCas13a (45 -90 nM) and LwaCas13a-crRNA (45 -90 nM) for the s gene. (B) PsmCas13b-based detection of purified N amplicon at different concentration of PsmCas13b (45 -135 nM) and PsmCas13b-crRNA (45 -135 nM) for the n gene. (C) Identifying optimal buffer conditions for LwaCas13a and PsmCas13b. The multiplexed CRISPR-based detection reaction prepared in Tris-HCl or HEPES buffer

The linear correlation between qPCR Ct value and RNA copy number obtained from ddPCR.RT-qPCR or ddPCR analyses were performed on paired samples from a dilution series of RNA extract from the cultured SARS-CoV-2 Wuhan strain. The experiment was carried out in triplicate (Appendix Table 1 ). Associated instructions were described in the Materials and Methods section. Linear regression analysis was performed. (Appendix Figure 1) Appendix Figure 1 A